Protective actions of a luminally acting 5-HT
5-HT4 receptor
colitis
mucosal serotonin signaling
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
23
08
2023
received:
28
04
2023
accepted:
24
08
2023
medline:
7
11
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
5-hydroxytryptamine 4 receptors (5-HT The dextran sodium sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), and interleukin 10 knockout (IL-10KO) models of colitis were used to test the protective effects of the luminally acting 5-HT Daily enema of 5HT4-LA1 attenuated the development of, and accelerated recovery from, active colitis. Enema administration of 5HT4-LA1 did not attenuate the development of colitis in 5-HT Luminally restricted 5-HT
Sections du résumé
BACKGROUND
BACKGROUND
5-hydroxytryptamine 4 receptors (5-HT
METHODS
METHODS
The dextran sodium sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), and interleukin 10 knockout (IL-10KO) models of colitis were used to test the protective effects of the luminally acting 5-HT
KEY RESULTS
RESULTS
Daily enema of 5HT4-LA1 attenuated the development of, and accelerated recovery from, active colitis. Enema administration of 5HT4-LA1 did not attenuate the development of colitis in 5-HT
CONCLUSIONS AND INFERENCES
CONCLUSIONS
Luminally restricted 5-HT
Substances chimiques
Serotonin
333DO1RDJY
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14673Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK131044
Pays : United States
Organisme : NCCIH NIH HHS
Pays : United States
Organisme : NCCIH NIH HHS
Pays : United States
Organisme : NIDDK NIH HHS
Pays : United States
Informations de copyright
© 2023 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Mawe GM, Hoffman JM. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473-486.
Spohn SN, Mawe GM. Non-conventional features of peripheral serotonin signalling - the gut and beyond. Nat Rev Gastroenterol Hepatol. 2017;14(7):412-420.
Bischoff SC, Mailer R, Pabst O, et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G685-G695.
Kim JJ, Bridle BW, Ghia JE, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013;190(9):4795-4804.
Li N, Ghia JE, Wang H, et al. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011;178(2):662-671.
Idzko M, Panther E, Stratz C, et al. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol. 2004;172(10):6011-6019.
Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology. 2012;142(4):844-854 e844.
van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131(1):117-129.
Spohn SN, Bianco F, Scott RB, et al. Protective actions of epithelial 5-Hydroxytryptamine 4 receptors in Normal and inflamed colon. Gastroenterology. 2016;151(5):933-944.e933.
De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99-112.
Konen JR, Haag MM, Guseva D, et al. Prokinetic actions of luminally acting 5-HT4 receptor agonists. Neurogastroenterol Motil. 2021;33(4):e14026.
Han C, Geng Q, Qin J, Li Y, Yu H. Activation of 5-Hydroxytryptamine 4 receptor improves colonic barrier function by triggering mucin 2 production in a mouse model of type 1 diabetes. Am J Pathol. 2022;192(6):876-886.
Pan H, Galligan JJ. 5-HT1A and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol. 1994;266(2 Pt 1):G230-G238.
Liu M, Geddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of 5-HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1148-G1163.
Galligan JJ. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav Brain Res. 1996;73(1-2):199-201.
Poole DP, Xu B, Koh SL, et al. Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. Cell Tissue Res. 2006;325(3):413-422.
Pan H, Galligan JJ. Effects of 5-HT1A and 5-HT4 receptor agonists on slow synaptic potentials in enteric neurons. Eur J Pharmacol. 1995;278(1):67-74.
Tonini M, Galligan JJ, North RA. Effects of cisapride on cholinergic neurotransmission and propulsive motility in the Guinea pig ileum. Gastroenterology. 1989;96(5 Pt 1):1257-1264.
Makimoto N, Sakurai-Yamashita Y, Furuichi A, et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine. Jpn J Pharmacol. 2002;90(1):28-35.
Fang X, Liu S, Wang XY, et al. Neurogastroenterology of tegaserod (HTF 919) in the submucosal division of the Guinea-pig and human enteric nervous system. Neurogastroenterol Motil. 2008;20(1):80-93.
Hockley JRF, Taylor TS, Callejo G, et al. Single-cell RNAseq reveals seven classes of colonic sensory neuron. Gut. 2019;68(4):633-644.
Okumura M, Hamada A, Ohsaka F, Tsuruta T, Hira T, Sonoyama K. Expression of serotonin receptor HTR4 in glucagon-like peptide-1-positive enteroendocrine cells of the murine intestine. Pflugers Arch. 2020;472(10):1521-1532.
Tam FS, Hillier K, Bunce KT, Grossman C. Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle. Br J Pharmacol. 1995;115(1):172-176.
McLean PG, Coupar IM, Molenaar P. A comparative study of functional 5-HT4 receptors in human colon, rat oesophagus and rat ileum. Br J Pharmacol. 1995;115(1):47-56.
Prins NH, Van Haselen JF, Lefebvre RA, Briejer MR, Akkermans LM, Schuurkes JA. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol. 1999;127(6):1431-1437.
Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol. 2000;129(8):1601-1608.
Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf). 2015;213(3):561-574.
Bhattarai Y, Jie S, Linden DR, et al. Bacterially derived tryptamine increases mucus release by activating a host receptor in a mouse model of inflammatory bowel disease. iScience. 2020;23(12):101798.
Bhattarai Y, Williams BB, Battaglioli EJ, et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe. 2018;23(6):775-785.e775.
Kaji I, Akiba Y, Said H, Narimatsu K, Kaunitz JD. Luminal 5-HT stimulates colonic bicarbonate secretion in rats. Br J Pharmacol. 2015;172(19):4655-4670.
Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. FASEB J. 1996;10(12):1398-1407.
Fukudo S, Nakamura M, Hamatani T, Kazumori K, Miwa H. Efficacy and safety of 5-HT4 receptor agonist Minesapride for irritable bowel syndrome with constipation in a randomized controlled trial. Clin Gastroenterol Hepatol. 2021;19(3):538-546.e538.
Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol. 2006;4(5):605-613.
Tack J. Prucalopride: a new drug for the treatment of chronic constipation. Expert Rev Gastroenterol Hepatol. 2009;3(4):337-343.
Tack J, Camilleri M, Dubois D, Vandeplassche L, Joseph A, Kerstens R. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. Neurogastroenterol Motil. 2015;27(3):397-405.
Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 2014;26(1):21-27.
Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357-365.
Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(10):1701-1708.
Yang H, Ma T. Luminally acting agents for constipation treatment: a review based on literatures and patents. Front Pharmacol. 2017;8:418.
Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745-767.
Anderson JL, May HT, Bair TL, Muhlestein JB, Horne BD, Carlquist JF. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. J Cardiovasc Pharmacol Ther. 2009;14(3):170-175.
Liu MT, Kuan YH, Wang J, Hen R, Gershon MD. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci. 2009;29(31):9683-9699.
Goto K, Kato G, Kawahara I, et al. In vivo imaging of enteric neurogenesis in the deep tissue of mouse small intestine. PLoS One. 2013;8(1):e54814.
Matsuyoshi H, Kuniyasu H, Okumura M, et al. A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Neurogastroenterol Motil. 2010;22(7):806-813.e226.
Kawahara I, Kuniyasu H, Matsuyoshi H, et al. Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5-HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats. Am J Physiol Gastrointest Liver Physiol. 2012;302(6):G588-G597.
Grider JR, Kuemmerle JF, Jin JG, et al. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol. 1996;270(5 Pt 1):G778-G782.